SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 2167083

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 2167083

Respiratory Syncytial Virus - Pipeline Insight, 2026

PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 2500
PDF & Excel (2-3 User License)
USD 4375
PDF & Excel (Site License)
USD 5625

Add to Cart

DelveInsight's, "Respiratory Syncytial Virus - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Respiratory Syncytial Virus: Understanding

Respiratory Syncytial Virus: Overview

RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults. RSV spreads through respiratory droplets and can survive on surfaces for several hours. While most infections are self-limiting, severe cases may require hospitalization, and preventive measures such as good hygiene and vaccination are essential in managing its spread.

Symptoms of RSV infection usually include runny nose; decrease in appetite; coughing; sneezing fever; wheezing. These symptoms usually appear in stages and not all at once. In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. RSV can also cause more severe infections such as bronchiolitis, an inflammation of the small airways in the lung, and pneumonia, an infection of the lungs. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age. People infected with RSV usually show symptoms within 4 to 6 days after getting infected.

RSV is highly contagious and it spreads through droplet transmission. When a person with the infection coughs or sneezes, secretions from their respiratory tract containing the virus are passed out into the air. A person is usually contagious for 3 to 8 days, but young children and those with a weakened immune system may still be able to pass it on for up to 4 weeks, even after their symptoms disappear. People infected with RSV are usually contagious for 3 to 8 days. However, some infants, and people with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.

Diagnosis of Respiratory Syncytial Virus (RSV) infections primarily involves clinical evaluation based on symptoms such as wheezing, coughing, and difficulty breathing, particularly in infants and young children. Laboratory tests include antigen detection, polymerase chain reaction (PCR) assays, and viral culture from nasal or throat swabs. Rapid diagnostic tests can provide results within hours, aiding in the timely management of the infection. Chest X-rays and blood tests may be performed to assess the severity of the disease and rule out other conditions.

Most RSV infections resolve on their own in a week or two. Antiviral drug called palivizumab is available to prevent severe RSV illness in high-risk infants (born prematurely or with congenital heart disease or chronic lung disease). However, the use of palivizumab is limited as it can only be used in certain children considered at high risk for complications, does not help cure or treat children already suffering from serious RSV disease, and cannot prevent RSV infection.

"Respiratory Syncytial Virus- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory Syncytial Virus pipeline landscape is provided which includes the disease overview and Respiratory Syncytial Virus treatment guidelines. The assessment part of the report embraces, in depth Respiratory Syncytial Virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus.

Respiratory Syncytial Virus Emerging Drugs Chapters

This segment of the Respiratory Syncytial Virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory Syncytial Virus Emerging Drugs

  • Zelicapavir: Enanta Pharmaceuticals

Zelicapavir (EDP-938) is an oral, once-daily antiviral developed by Enanta Pharmaceuticals for the treatment of respiratory syncytial virus (RSV) infection. It is a potent inhibitor of the RSV nucleoprotein (N-protein), targeting the virus's replication machinery. By inhibiting the N-protein, zelicapavir prevents viral replication and the production of new virions, thereby differing from RSV fusion inhibitors, which act by blocking viral entry. Zelicapavir, Enanta's lead N-protein inhibitor, is being developed for the treatment of RSV infection, and has been granted Fast Track designation by the US Food and Drug Administration. Zelicapavir is a nanomolar inhibitor of both RSV-A and RSV-B activity. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.

  • SCB-1022: Clover Biopharmaceuticals

SCB-1022, developed by Clover Biopharmaceuticals, is a recombinant bivalent respiratory combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. The vaccine is based on prefusion-stabilized F (PreF) protein subunit antigens produced using Clover's Trimer-Tag vaccine technology platform, with the aim of inducing neutralizing antibody responses against both respiratory viruses. SCB-1022 is being evaluated primarily in older adults aged 60-85 years, a population at increased risk of severe respiratory disease. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.

  • mRNA-1365: Moderna, Inc.

mRNA-1365 is an investigational combination respiratory vaccine developed by Moderna, Inc. that targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The vaccine is designed as a part of its respiratory vaccine portfolio to address major causes of lower respiratory tract infections, particularly in pediatric populations and other vulnerable groups. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.

  • MDL-001: Model Medicines

MDL-001 is an investigational, oral, direct-acting broad-spectrum antiviral developed by Model Medicines for multiple respiratory and hepatic viral infections, including respiratory syncytial virus (RSV). The company describes MDL-001 as a non-nucleoside inhibitor that targets the conserved RdRp Thumb-1 allosteric pocket of viral RNA-dependent RNA polymerases, thereby blocking viral RNA synthesis. For RSV, Model Medicines reported in vitro antiviral activity with an EC50 of 79.4 nM, representing approximately a 416-fold improvement in potency compared with ribavirin in the company's testing. Currently, the drug is in the Preclinical stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.

Respiratory Syncytial Virus: Therapeutic Assessment

This segment of the report provides insights about the different Respiratory Syncytial Virus drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Respiratory Syncytial Virus

There are approx. 50+ key companies which are developing the therapies Respiratory Syncytial Virus. The companies which have their Respiratory Syncytial Virus drug candidates in the most advanced stage, i.e. Phase II include, Enanta Pharmaceuticals and others.

  • Phases

DelveInsight's report covers around 55+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory Syncytial Virus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory Syncytial Virus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory Syncytial Virus drugs.

Respiratory Syncytial Virus Report Insights

  • Respiratory Syncytial Virus Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Respiratory Syncytial Virus Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Respiratory Syncytial Virus drugs?
  • How many Respiratory Syncytial Virus drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory Syncytial Virus?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory Syncytial Virus therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Respiratory Syncytial Virus and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Enanta Pharmaceuticals
  • Shionogi
  • Clover Biopharmaceuticals
  • Model Medicines
  • Moderna, Inc.
  • GSK
  • Blue Lake Biotechnology Inc.
  • Eradivir Inc.
  • Innorna Co., Ltd.
  • SK Bioscience

Key Products

  • Zelicapavir
  • S-337395
  • SCB-1022
  • SCB-1033
  • SCB-1019
  • MDL-001
  • mRNA-1365
  • GSK5893818
  • BLB201
  • EV148
  • IN006
  • IN029
  • RSM01
Product Code: DIPI0501

Table of Contents

Introduction

Executive Summary

Respiratory Syncytial Virus: Overview

  • Introduction
  • Signs and Symptoms
  • Transmission
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Respiratory Syncytial Virus- DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Drug name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

Zelicapavir: Enanta Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

mRNA-1365: Moderna, Inc.

  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products

  • Comparative Analysis

MDL-001: Model Medicines

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Respiratory Syncytial Virus Key Companies

Respiratory Syncytial Virus Key Products

Respiratory Syncytial Virus - Unmet Needs

Respiratory Syncytial Virus - Market Drivers and Barriers

Respiratory Syncytial Virus - Future Perspectives and Conclusion

Respiratory Syncytial Virus Analyst Views

Respiratory Syncytial Virus Key Companies

Product Code: DIPI0501

List of Tables

  • Table 1: Total Products for Respiratory Syncytial Virus
  • Table 2: Late Stage Products
  • Table 3: Mid Stage Products
  • Table 4: Early Stage Products
  • Table 5: Pre-clinical & Discovery Stage Products
  • Table 6: Assessment by Product Type
  • Table 7: Assessment by Stage and Product Type
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Molecule Type
  • Table 11: Assessment by Stage and Molecule Type
  • Table 12: Inactive Products

List of Figures

  • Figure 1: Total Products for Respiratory Syncytial Virus
  • Figure 2: Late Stage Products
  • Figure 3: Mid Stage Products
  • Figure 4: Early Stage Products
  • Figure 5: Preclinical and Discovery Stage Products
  • Figure 6: Assessment by Product Type
  • Figure 7: Assessment by Stage and Product Type
  • Figure 8: Assessment by Route of Administration
  • Figure 9: Assessment by Stage and Route of Administration
  • Figure 10: Assessment by Molecule Type
  • Figure 11: Assessment by Stage and Molecule Type
  • Figure 12: Inactive Products
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!